Open Medicine
(Oct 2024)
The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study
Jonusas Justinas,
Drevinskaitė Mingailė,
Linkeviciute-Ulinskiene Donata,
Ladukas Adomas,
Patašius Aušvydas,
Zabulienė Lina,
Smailytė Giedrė
Affiliations
Jonusas Justinas
Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Drevinskaitė Mingailė
Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Linkeviciute-Ulinskiene Donata
The Medical Clinic, Västerås Central Hospital, 72189, Västerås, Sweden
Ladukas Adomas
Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Patašius Aušvydas
Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Zabulienė Lina
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101, Vilnius, Lithuania
Smailytė Giedrė
Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
DOI
https://doi.org/10.1515/med-2024-1017
Journal volume & issue
Vol. 19,
no. 1
Abstract
Read online
The aim of this study was to determine the association between insulin glargine usage and the potential increase in cancer risk among the Lithuanian population diagnosed with type 2 diabetes mellitus (T2DM).
WeChat QR code
Close
